In addition, a large-scale study of 77 radiotherapy-induced sarcomas reported a higher frequency of c-MYC amplification and losses of CDKN2A and CDKN2B in radiotherapy-induced sarcomas than in sporadic sarcomas [42]. This evidence concerns the gene CDKN2A and sarcoma.